WVE - Wave Life Sciences Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
37.60
+1.07 (+2.93%)
At close: 4:00PM EST

37.60 0.00 (0.00%)
After hours: 4:42PM EST

Stock chart is not supported by your current browser
Previous Close36.53
Open36.87
Bid30.20 x 1000
Ask40.00 x 800
Day's Range36.78 - 37.61
52 Week Range32.25 - 56.00
Volume197,248
Avg. Volume295,063
Market Cap1.256B
Beta (3Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-4.89
Earnings DateAug 14, 2017 - Aug 18, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.57
Trade prices are not sourced from all markets
  • Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
    PR Newswire3 days ago

    Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer

    Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs ...

  • Why Wave Life Sciences Ltd.’s (NASDAQ:WVE) CEO Pay Matters To You
    Simply Wall St.17 days ago

    Why Wave Life Sciences Ltd.’s (NASDAQ:WVE) CEO Pay Matters To You

    Paul Bolno has been the CEO of Wave Life Sciences Ltd. (NASDAQ:WVE) since 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies Read More...

  • New life science internship program launches to help boost diversity
    American City Business Journals17 days ago

    New life science internship program launches to help boost diversity

    In the inaugural year of Project Onramp, 50 low-income students will be placed in paid science, engineering, communication, marketing and other internships with local biotech and medical device companies, according to the announcement made Tuesday.

  • Here's Why Wave Life Sciences Is Crashing Today
    Motley Fool22 days ago

    Here's Why Wave Life Sciences Is Crashing Today

    Investors aren't too thrilled about this biotech's latest share offering.

  • GlobeNewswire22 days ago

    Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

    Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten public offering of 3,950,000 of its ordinary shares at a price to the public of $38.00 per ordinary share. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 592,500 of its ordinary shares on the same terms and conditions.

  • GlobeNewswire23 days ago

    Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

    Wave Life Sciences Ltd. (WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of its ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering on the same terms and conditions. All of the shares in the offering will be sold by Wave Life Sciences.

  • FDA pilot program could help Wave avoid orphan-drug pitfalls
    American City Business Journalslast month

    FDA pilot program could help Wave avoid orphan-drug pitfalls

    Wave will work with FDA officials during the pilot program to design a Phase 2-3 clinical trial with a reduced number of placebo patients, tweaking standards that have stymied other rare disease products.

  • Here's Why Sarepta Therapeutics Fell 15.7% in December
    Motley Foollast month

    Here's Why Sarepta Therapeutics Fell 15.7% in December

    A competitive threat is advancing, but investors might want to view last month's pullback as an opportunity.

  • GlobeNewswirelast month

    Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

    Wave Life Sciences Ltd. (WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the planned Phase 2/3 efficacy and safety trial for its lead Duchenne muscular dystrophy (DMD) clinical program has been selected for the U.S. Food and Drug Administration (FDA) pilot program for complex innovative trial designs (CID). The selection was based on the design of Wave’s Phase 2/3 clinical trial of suvodirsen (WVE-210201), an investigational therapy for boys with DMD who are amenable to exon 51 skipping.

  • Simply Wall St.2 months ago

    How Financially Strong Is Wave Life Sciences Ltd. (NASDAQ:WVE)?

    The direct benefit for Wave Life Sciences Ltd. (NASDAQ:WVE), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the Read More...

  • GlobeNewswire2 months ago

    Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)

    Wave Life Sciences Ltd. (WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial. Based on results from four ascending dose cohorts in the Phase 1 trial and pending final analysis, Wave has selected a dose for its planned Phase 2/3 clinical trial of WVE-210201, which it intends to initiate in 2019.

  • Benzinga3 months ago

    Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

    With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week.  The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...

  • Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

    Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.40% and -16.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Wave Life Sciences: 3Q Earnings Snapshot

    The Singapore-based company said it had a loss of $1.28 per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...

  • Simply Wall St.4 months ago

    Should You Be Holding Wave Life Sciences Ltd (NASDAQ:WVE) Right Now?

    Anyone researching Wave Life Sciences Ltd (NASDAQ:WVE) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and Read More...

  • Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
    Zacks6 months ago

    Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

    Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.82% and -33.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Wave Life Sciences: 2Q Earnings Snapshot

    The Singapore-based company said it had a loss of $1.23 per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...